Tamoxifen and giant endometrial polyp

We present the case of a woman with a giant endometrial polyp of uncommon dimension who was receiving adjuvant tamoxifen for breast cancer. In her gynecologic examination, she had a mass measuring 3 x 4 x 4 cm protruding from the cervical os. The mass was extirpated under general anesthesia. The mass originated from the endometrial cavity. The endometrial polyp measured 10 x 6 x 3 cm macroscopically and was found to be benign under microscopic examination. We conclude that physicians should be aware of the confounding effects of tamoxifen on the histological and ultrasonographic appearance of the endometrium.

Tamoxifen; Endometrial polyp; Breast cancer

[1]Caschetto S., Cassaro N., Consalvo P., Caragliano L.: “Tamoxifen and giant endometrial polyps”. Minerva Ginecol., 2000, 52, 459.

[2] Neven P., De Muylder X., Van Belle Y., Vanderick G., De Muylder E.:“Tamoxifen and the uterus and endometrium”. Lancet, 1989, 2, 375.

[3] Barakat R.R., Wang G., Curtin J., Vlamis V., Hoskins W.J.: “Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features”. Gynecol. Oncol., 1994, 55, 164.

[4] Cohen I., Perel E., Flex D., Tepper R., Altars M.M., Cordoba M., Beyth Y.: “Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gynecologicaly symptomatic and asymptomatic breast cancer patients”. J. Clin. Pathol., 1999, 52, 278.

[5] Schlesinger C., Kamoi S., Ascher S., Kendell M., Lage J.M., Silverberg S.G.: “Endometrial polyps: a comparison study of patients receiving tamoxifen with two control groups”. Int. J. Gynecol. Pathol., 1998, 17, 302.

[6] Deligdisch L., Kalir N., Cohen C.J., de Latour M., Le Bouedec G., Penault-Llorca F.: “Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer”. Gynecol. Oncol., 2000, 78, 181.

[7] Cohen I., Azaria R., Shapira J., Dror Y., Tepper R.: “The significance of secondary ultrasonographic endometrial thickening in postmenopausal tamoxifen-treated women”. Cancer, 2002, 94, 3101.

[8] Cohen I., Altaras M.M., Shapira J., Tepper R., Rosen D.J.D., Cordoba M., Beyth Y.: “Time-dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic, postmenopausal breast cancer patients”. Int. J. Gynecol. Pathol., 1996, 15, 152.

[9] Cohen I., Azaria R., Bernheim J., Shapira J., Beyth Y.: “Risk factors of endometrial polyps resected from postmenopausal patients with breast carcinoma treated with tamoxifen”. Cancer, 2001, 92, 1151.

[10] Bergman L., Beelen M.L., Gallee M.P.: “Risk and prognosis of endometrial cancer after tamoxifen for breast cancer: Comprehensive Cancer Centres' ALERT Group-Assessment of Liver and Endometrial Cancer Risk Following Tamoxifen”. Lancet, 2000, 356, 881.

[11] Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E. et al.: “Tamoxifen therapy for breast cancer and endometrial cancer risk”. J. Natl Cancer Inst., 1999, 91, 1654.

[12] Mourits M.J., Van der Zee A.G., Willemse P.H., Ten Hoor K.A., Hollema H., De Vries E.G.: “Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen”. Gynecol. Oncol., 1999, 73, 21.

[13] Cohen I., Rosen D.J., Tepper R., Cordoba M., Shapira Y., Altaras M.M. et al.: “Ultrasonographic evaluation of the endometrium and correlation with endometrial sampling in postmenopausal patients treated with tamoxifen”. J. Ultrasound Med., 1993, 12, 275.